Paget Disease of Bone

Detailed Overview

The disease begins with an intense phase of osteoclastic overactivity, leading to lytic lesions. This is followed by a mixed phase where compensatory osteoblastic activity increases, but the new bone is laid down in a haphazard "mosaic" pattern rather than normal lamellar bone. The resulting bone is hypervascular, enlarged, and prone to deformity and fracture. While many patients remain asymptomatic, it can lead to severe bone pain, skeletal deformities, secondary osteoarthritis, and neurological complications due to nerve compression. Rare but life-threatening complications include high-output heart failure and malignant transformation to osteosarcoma.

Epidemiology & Demographics

Prevalence is approximately 1-2% in white populations of European descent over age 55, rising to 8% in those over 80. Incidence has been mysteriously declining over the last 25 years. Slightly more common in men (ratio 1.5:1). Rare in Asian and African populations.

Etiological Mechanism

The exact cause is controversial but appears to be a mix of genetic predisposition and environmental triggers. Mutations in the SQSTM1 gene (encoding p62) are found in 10-50% of familial cases and 5-15% of sporadic cases. A slow virus infection (such as paramyxoviruses like measles or respiratory syncytial virus) affecting osteoclasts has long been hypothesized as an environmental trigger.

Primary Causes

Primary cause is abnormal osteoclast function, specifically increased size and number of osteoclasts with excessive nucleation (up to 100 nuclei per cell vs normal 3-10). These hyperactive osteoclasts drive the chaotic remodeling cycle.

• Age: Risk increases significantly after age 55.
• Genetics: First-degree relatives of a patient with Paget disease have a 7- to 10-fold increased risk.
• European Ancestry: Highest prevalence in UK, Australia, New Zealand, and North America.

The pathophysiologic hallmark is increased bone turnover. Initially, there is a dramatic increase in osteoclast-mediated bone resorption (osteolytic phase). Osteoclasts in Paget disease are larger, more numerous, and contain viral-like nuclear inclusion bodies. This is followed by a compensatory but frantic increase in osteoblast activity (mixed phase), where new woven bone is rapidly formed. Eventually, osteoblast activity predominates but is disorganized, creating a 'mosaic' pattern of cement lines without structural integrity (osteosclerotic phase). The marrow spaces become filled with highly vascular fibrous tissue.

Characteristic Clinical Presentation

• Bone Pain: Deep, aching pain, often worse at night and at rest, commonly in the pelvis, spine, or femur.
• Joint Pain: Secondary osteoarthritis pain occurring in joints adjacent to pagetic bone (e.g., hip or knee).
• Hearing Loss: Conductive or sensorineural hearing loss due to pagetic involvement of the temporal bone and ossicles.
• Headache: Dull head pain or increasing hat size due to skull enlargement.

Physical Examination Signs

• Bowing of long bones (e.g., femur, tibia)
• Frontal bossing and enlarged skull
• Warmth over affected bone (due to hypervascularity)
• Kyphosis or neurological deficits (e.g., radiculopathy from spinal stenosis)

• Fractures: Pathologic fractures, characteristically 'chalk stick' fractures in long bones.
• Osteosarcoma: Malignant transformation occurring in <1% of patients, presenting as new, worsening pain or swelling.
• High-Output Heart Failure: Can occur if >15% of the skeleton is involved due to massive hypervascularity acting as AV fistulas.

Diagnostic Criteria & Guidelines

Diagnosis is primarily radiographic and biochemical. Radiographs showing classic features (cortical thickening, bone enlargement, mixed lytic/sclerotic lesions) combined with isolated elevation of serum alkaline phosphatase (ALP) with normal GGT and calcium. A radionucleotide bone scan (Technetium-99m) is used to determine the full extent of skeletal involvement.

Differential Diagnosis

• Metastatic Bone Disease (especially prostate or breast cancer)
• Osteomalacia
• Fibrous Dysplasia
• Primary Hyperparathyroidism

Laboratory Tests & Biomarkers

• Serum Alkaline Phosphatase (ALP): Elevated (often 2-10x normal, e.g., >300 U/L), reflecting osteoblast activity.
• Procollagen type I N-terminal propeptide (PINP): Elevated, highly sensitive marker of bone formation.
• Serum Calcium: Typically normal (may be elevated if immobilized).
• Urine N-telopeptide (NTX): Elevated, reflecting increased bone resorption.

Imaging Modalities & Findings

• X-ray:
• Bone Scan:

• Osteolytic Phase
  Predominant osteoclastic bone resorption; wedge-shaped lytic fronts on X-ray.
• Mixed Phase
  Concurrent rapid bone formation and resorption; cortical thickening begins.
• Osteosclerotic Phase
  Dense, enlarged, disorganized woven bone formation predominates; bone is structurally weak.

Second-Line & Adjunctive Therapy

Subcutaneous Calcitonin (salmon) 100 IU daily or every other day, used only if bisphosphonates are contraindicated or poorly tolerated (e.g., severe renal impairment). Oral Pamidronate or Ibandronate can also be considered.

Surgical & Procedural Management

Total joint arthroplasty for severe secondary osteoarthritis. Osteotomy for severe bowing causing pain or functional impairment. Decompression laminectomy for spinal stenosis/nerve compression. Surgical fixation for pathologic fractures.

Recommended Lifestyle Changes

Patient Counseling & Advice

Explain that the disease is localized and not a systemic cancer. Emphasize that while the abnormal bone cannot be reversed, treatments are highly effective at halting progression and reducing pain. Warn about the small risk of osteonecrosis of the jaw and atypical femur fractures with bisphosphonates. Advise them to seek immediate evaluation for sudden severe bone pain (risk of fracture or sarcoma).

Follow-Up & Monitoring Schedule

Check serum ALP or PINP at 3-6 months post-treatment to assess response. Then monitor ALP every 6-12 months. Retreatment is indicated if symptoms relapse or ALP rises >25% above nadir.

Preventive Strategies

No known prevention for the disease itself. Prevention focuses on avoiding complications (fractures, secondary OA) through early bisphosphonate treatment in active disease.

Generally excellent with modern bisphosphonate therapy, which can achieve prolonged remission (often >5 years after a single zoledronic acid dose). Prognosis is worse if osteosarcoma develops (<1% survival at 5 years if metastatic).